BD (NYSE:BDX) announced today that it will collaborate with Mayo Clinic Platform to perform detailed post-market surveillance.
Franklin Lakes, New Jersey-based BD’s collaboration with Mayo Clinic Platform will access de-identified patient data from the Mayo Clinic Platform_Discover to perform post-market surveillance of the company’s products and fuel innovation, unlocking a faster, more efficient path to market with the overarching goal of improving patient care.
According to a news release, Mayo Clinic Platform_Discover represents a robust de-identified data set available from 10 million patients, including both structured and unstructured data, images, 1.2 billion lab test results, 3 million echocardiograms and more than 640 million clinical notes.
BD intends to use the platform’s capabilities in data mining, next-generation artificial intelligence (AI) and machine learning tools to analyze real-world data to generate insight into the patient experience to help accelerate and enhance innovation around existing products and unmet needs.
“For years, randomized control trials have been considered the gold-standard in evaluating safety and efficacy for medical devices, but experts from industry and academia who are examining the tight parameters around clinical trials are seeing added value in leveraging insights from real-world data to truly understand whether we are meeting patients’ needs,” BD VP of Global Clinical Affairs and Medical Affairs Strategy Lisa Boyle said in the release. “We need to be leveraging real-world evidence, using datasets like those from Mayo Clinic Platform, to understand the many parameters that we wouldn’t normally capture in a clinical trial and understand patients’ care pathways and address the needs of diverse patients in order to establish better solutions for better outcomes and experiences.”
BD also plans to use the platform’s rich historical data for predictive modeling, allowing for more accurate forecasts related to device use. The aim of that is to increase efficiency for new clinical trials and to generate evidence. Mayo Clinic’s data will also support new claims for its products and streamline medical device regulatory submissions.
“Our next-generation analytical tools and curated de-identified patient data create a dynamic, privacy-protected environment for discovery that few in the industry can provide,” Mayo Clinic Platform VP for Product Portfolio Steven Bethke said. “Mayo Clinic Platform_Discover enables medical technology leaders such as BD to derive key insights as they develop solutions for their customers and patients as quickly and safely as possible.”